Search Results
Results found for "Keltic Pharma Therapeutics"
- Dr. Juan José Fung - Dr. GPCR Podcast
Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.
- Molecular insights into psychedelic drug action
actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic
- Molecular targets of psychedelic-induced plasticity
toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic
- Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild trauma
This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model
- G protein-coupled receptor signaling: transducers and effectors
physiological functions and in a large number of Food and Drug Administration (FDA)-approved drugs as therapeutic
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
– CXCR4 oligomer disruption boosts therapeutic response in lymphoid neoplasms Dr.
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
combination of Steyaert’s fundamental research and his ability to apply the research to the development of therapeutic
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new therapeutics ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10), 2509.
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
These advances have paved the way for development of novel ligands for different therapeutic applications
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell...
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Industry News Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover SMILES-based de novo molecular generation with curriculum and deep reinforcement learning Structure Therapeutics
- From DNA day to GPCR genomics
GPCR-targeted drugs, and the exploration of GPCRs as key regulators of physiological processes and therapeutic analysis, have facilitated drug discovery and design targeting GPCRs, leading to the development of novel therapeutics
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic
- Viral G Protein-Coupled Receptors Encoded by β- and γ-Herpesviruses
Finally, we briefly discuss the therapeutic targeting of vGPCRs as future treatment of acute and chronic
- 📰 GPCR Weekly News, May 22 to 28, 2023
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Patients with Idiopathic Pulmonary Fibrosis Exscientia Business Update for First Quarter 2023 Structure Therapeutics
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
GHSR1a The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential as a therapeutic Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH)
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development of therapeutic
- 📰 GPCR Weekly News, July 17 to July 23, 2023
GPCR Symposium on GPCRs as Therapeutic Modalities on September 22nd. Domain Therapeutics announces the European Patent Office decision to grant a patent for its proprietary
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
receptor subfamily, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
development of more personalised therapies tailored to the genetic makeup of individual patients, enhancing therapeutic that can drive the early stages of target and lead identification, combat drug resistance, and refine therapeutic
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted therapeutics
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics
- 📰 GPCR Weekly News, June 5 to 11, 2023
Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics Confo Therapeutics Enters Into Research Collaboration For GPCR-Targeting Antibody Discovery With AbCellera
- 📰 GPCR Weekly News, January 16 to 22, 2023
Industry News Addex Provides Corporate Update And Financial Guidance Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
The identification of unified innate threat pathways may provide insights into developing therapeutic
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
; understanding the role of DNAJC13 in GPCR trafficking could profoundly affect the development of therapeutic
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics





